Pharmaceutical - Pharmaceutical, North America, Eisai

Filter

1 to 25 of 31 results

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA

02-01-2014

The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

Eisai’s R&D organization undergoes “transformation”

Eisai’s R&D organization undergoes “transformation”

30-11-2013

Japanese drugmaker Eisai's president and chief executive, Haruo Naito, says that the company's R&D organization,…

Asia-PacificEisaiEuropeManagementNorth AmericaPharmaceuticalResearchUSA

Eisai enters agreement to develop treatments for neglected tropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases

11-11-2013

Eisai (TYO: 4523) has entered into a global agreement with the Broad Institute to jointly discover and…

Asia-PacificEisaiNorth AmericaPharmaceuticalResearchTropical diseases

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December

15-10-2013

Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

FDA clears Eisai Zonegran facility in UK for US exports

FDA clears Eisai Zonegran facility in UK for US exports

15-10-2013

Eisai says the US Food and Drug Administration has approved the US supply of the epilepsy drug Zonegran…

EisaiEuropeNeurologicalNorth AmericaPharmaceuticalProductionRegulationZonegran

Eisai's launch plan for obesity drug Belviq in USA enters consumer phase

16-09-2013

The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Eisai's EMEA operation cleared as US supplier of Fycompa in USA

11-09-2013

The US Food and Drug Administration has approved the US supply of Japanese pharma major Eisai's (TYO:…

EisaiFycompaNeurologicalNorth AmericaPharmaceuticalProduction

Eisai launches legal action after "unreasonable" delay for its epilepsy drug

20-08-2013

Japanese drug major Eisai (TYO: 4523) has taken legal action in the USA over the delay of the recommendation…

EisaiFycompaNeurologicalNorth AmericaPharmaceuticalRegulation

Eisai gains Swiss approval for Zonegran and Canadian OK for Fycompa

11-07-2013

Japanese drug major Eisai (TYO: 4205) says that Zonegran (zonisamide) has been approved by Switzerland's…

EisaiEuropeFycompaNeurologicalNorth AmericaPharmaceuticalRegulationZonegran

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis

20-06-2013

The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Arena/Eisai's Belviq at last to launch in the USA

07-06-2013

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that its long-awaited weight loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments

03-06-2013

Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Arena and Eisai finally get DEA scheduling for obesity drug Belviq

08-05-2013

The long wait to get obesity drug Belviq (lorcaserin) to the US market, where it was approved by the…

Arena PharmaceuticalsBelviqEisaiMetabolicsNorth AmericaPharmaceuticalRegulation

FDA approves Eisai's Aciphex Sprinkle for GERD in children; Inovelon OKed in Japan

28-03-2013

Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has approved Aciphex…

AciphexAsia-PacificEisaiGastro-intestinalsInovelonNeurologicalNorth AmericaPharmaceuticalRegulation

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

Treatment landscape for thyroid carcinoma will change dramatically through 2021; report

05-02-2013

Through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the USA and Europe…

BayerdabrafenibEisaiEuropeGlaxoSmithKlinelenvatinibMarkets & MarketingNexavarNorth AmericaOncologyOXiGENEPharmaceuticalRochetrametinibZelborafZybrestat

Takeda sells non-Colcrys URL Pharma generic business to Sun Pharma; Eisai divests Gliadel Wafer in USA

17-12-2012

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), has entered into a definitive agreement…

Arbor PharmaceuticalsColcrysEisaiGenericsGliadelMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalSun Pharmaceutical IndustriesTakeda PharmaceuticalsURL Pharma

Insights on the US Alzheimer's disease market

03-12-2012

The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

FDA approves Eisai's Fycompa to treat epileptic seizures and Supernus' Oxtellar XR

23-10-2012

The US Food and Drug Administration yesterday approved Japanese drug major Eisai's (TYO: 4523) Fycompa…

EisaiFycompaNeurologicalNorth AmericaOxtellar XRPharmaceuticalRegulationSupernus Pharmaceuticals

Public Citizen sues FDA for failing to ban dangerous dose of Aricept

07-09-2012

The Food and Drug Administration has dragged its feet for too long on a petition calling on the agency…

AriceptEisaiLegalNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

News briefs: Priority review for ocriplasmin; Zonegran monotherapy in EU

03-07-2012

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR) says that the US Food and Drug Administration…

EisaiEuropeNeurologicalNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenicsZonegran

Eureka moment: US FDA approves first new obesity drug in 13 years

28-06-2012

After several years of investigation, and a rejection by the US regulator, the Food and Drug Administration…

Arena PharmaceuticalsBelviqEisailorcaserinMetabolicsNorth AmericaPharmaceuticalRegulation

Arena Pharma gets positive FDA panel vote for obesity drug; prophylactic Truvada backed

11-05-2012

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese licensing partner Eisai (TYO: 4523) got a…

Anti-viralsArena PharmaceuticalsBiotechnologyEisaiGilead ScienceslorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulationTruvada

1 to 25 of 31 results

Parexel

Parexel

Back to top